Background: Combined trastuzumab and intravenous vinorelbine yielded high clinical activity as preoperative treatment in patients (pts) with HER 2/neu positive breast cancer.
Patients And Methods: We tested a preoperative combination of trastuzumab with oral vinorelbine (oV) in pts with locally advanced (T2-T4 N0-3 M0) HER2-positive breast cancer. Trastuzumab was administered i.v q 3 wks and oV was administered at the dose of 55 mg/sqm on days 1 and 3 q 3 wks, for 8 courses. Pts with ER > or = 10% tumors received endocrine therapy with letrozole 2.5 mg/day, plus monthly triptorelin if premenopausal.
Results: Forty-five pts entered the study. The overall response rate (CR + PR) was 76% (95% CI: 60%-87%). pCR was observed in 4 pts (10%). Among ER-positive tumors 21/25 pts obtained a clinical response (84%) and two pts obtained a pCR (8%).
Conclusions: The combination of trastuzumab and oral vinorelbine demonstrated encouraging activity in patients with HER 2 positive ER-positive tumors. Alternative strategies should be investigated in patients with endocrine non responsive disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.breast.2009.12.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: osteonecrosis of the maxilla and mandible related to trastuzumab, docetaxel and carboplatin.
Oral Surg Oral Med Oral Pathol Oral Radiol
December 2024
Service of Oral Pathology, João de Barros Barreto University Hospital, Federal University of Para, Belem, Para, Brazil.
We present a case of a patient with HER-2 positive breast cancer who developed extensive areas of osteonecrosis in the mandible and maxilla due to the combination of trastuzumab, carboplatin, and docetaxel. The pathogenesis is discussed based on the literature.
View Article and Find Full Text PDFTolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.
Cancers (Basel)
December 2024
Phase IV Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been established as the standard of care in the adjuvant setting for HER2BC patients who do not obtain pCR. The ATD study aimed to evaluate the real-world tolerability of T-DM1 in this setting.
View Article and Find Full Text PDFA therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors' failure: A review of current and investigational treatment for HR+/Her2- breast cancer.
Crit Rev Oncol Hematol
December 2024
Medical Oncology Dept. Fondazione Poliambulanza, Brescia, Italy.
Article Synopsis
- - First-line combo treatments using CDK4/6 inhibitors with endocrine therapy have improved outcomes for advanced hormone receptor positive (HR+)/HER2- breast cancer, but resistance can develop over time.
- - ESR1 gene mutations contribute to resistance against aromatase inhibitors, which may inform the use of therapies like fulvestrant or new oral selective estrogen receptor degraders (SERDs).
- - New targeted treatments, such as PARP inhibitors for BRCA mutations and antibody-drug conjugates like trastuzumab deruxtecan, highlight the importance of personalized approaches and early intervention based on specific genetic changes in metastatic breast cancer.
Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study.
BMC Cancer
October 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Article Synopsis
- A new study investigates the effectiveness of combining pyrotinib, a targeted therapy, with metronomic oral etoposide chemotherapy in patients with heavily pretreated HER2-positive metastatic breast cancer (MBC). !* -
- Results from 22 patients show a median progression-free survival (PFS) of 9.0 months and overall survival (OS) of 27.0 months, indicating that the treatment is both effective and tolerable. !* -
- The combination treatment yielded a 30% objective response rate and an 80% disease control rate, with manageable side effects primarily including nausea, vomiting, and diarrhea. !*
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer.
Clin Pharmacokinet
October 2024
Pfizer Inc., 21717 30th Dr SE, Bothell, WA, 98021, USA.
Background And Objective: Tucatinib is a highly selective, oral, reversible, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor. Tucatinib is approved at a 300-mg twice-daily dose in adults in combination with trastuzumab and capecitabine for advanced HER2-postitive (HER2+) unresectable or metastatic breast cancer and in combination with trastuzumab for RAS wild-type HER2+ unresectable or metastatic colorectal cancer. This study sought to characterize the pharmacokinetics (PK) and assess sources of PK variability of tucatinib in healthy volunteers and in patients with HER2+ metastatic breast or colorectal cancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!